Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

Humana Inc. (HUM) announced pricing terms for its cash tender offers to purchase certain outstanding debt securities, totaling up to $1.5 billion. The offers include various senior notes due between 2027 and 2032, with specific acceptance priorities and caps. The total consideration per $1,000 principal amount varies by note series, ranging from $852.68 to $1,005.77. The offers expire on November 16, 2026, with a settlement date expected on November 18, 2026.

Original reporting
Published Nov 16, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities — source image
Decision brief

The 30-second read

$HUMNeutralMed
01

Why it matters

By publishing the offer yield components and total consideration per $1,000 principal, the company clarifies the economics for holders deciding whether to tender before the withdrawal deadline and expiration.

02

Market read

Traders in HUM credit can use the disclosed total consideration and reference yields to gauge likely tender behavior and near-term bond pricing around the offer window.

03

What to watch

Deal execution risk (conditions not satisfied), potential changes to tender cap/series cap, and how the reference yields map to current secondary-market levels for each note series.

Relevance 7/10Novelty 7/10Timing: today’s pricing terms, with withdrawal deadline and expiration at 5:00 p.m. ET and expected settlement on Nov. 18, 2026

Background

Humana previously announced cash tender offers for several series of its outstanding senior notes; this release provides the reference yield and total consideration used to price those offers.

Company-level read

Ticker impact

$HUMNeutralMedium confidence
Context

Humana sets reference yields and total consideration for its cash tender offers to repurchase multiple outstanding senior notes, including a $800m cap on 2031 notes.

Expected impact

Bond market likely prices in the tender economics around the stated total consideration, while equity impact is likely muted unless credit spreads widen materially.

Evidence & confidence

The release is a debt tender pricing update with explicit consideration per $1,000 principal and defined caps/proration, which is most directly tradable in the company’s credit rather than driving a clear equity catalyst.

Market effects

Provides a datapoint on managed-care issuers’ ongoing liability management via multi-series tender offers, which can influence relative credit spread expectations.

Primarily impacts US corporate bond markets and credit traders rather than broad regional equities.

Limited global spillover; the mechanics are US dollar-denominated notes tied to US Treasury reference yields.

Counterpoint

If proration or acceptance priority limits how much of each series is bought, the effective demand may be less than investors expect, reducing the support to bond prices.

Key entities

  • Humana Inc.

    Issuer conducting cash tender offers and setting reference yields and total consideration for multiple senior note series.

  • Barclays Capital Inc.

    Dealer manager for the tender offers.

  • BofA Securities, Inc.

    Dealer manager for the tender offers.

  • PNC Capital Markets LLC

    Dealer manager for the tender offers.

  • U.S. Bancorp Investments, Inc.

    Dealer manager for the tender offers.

Related articles

$HUMMed

Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

HUMANA INC (HUM) filed an SEC Form 8-K — Other Events. news release Humana Inc. 101 East Main Street Louisville, KY 40202 Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities Louisville, KY - November 16, 2026 - Humana Inc. (NYSE: HUM) (“ Humana ”, “ we ”, or “ our ”) today announce

$HUMHigh

Why is Humana stock climbing today?

Humana Inc (HUM) stock rose 2.2% in pre-market trading after RBC Capital upgraded it to 'Outperform' and raised its price target to $563. The move follows Humana's Q3 2026 earnings beat, with revenue of $41.16 billion and raised full-year EPS guidance to at least $9.50. Multiple analysts have upgraded the stock, citing improving Medicare Advantage ratings and cost outlook.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.